Abstract
Impulse Control Disorders (ICDs) and related disorders are common side effects of dopaminergic treatment in Parkinson’s Disease (PD) and are associated with negative effects on mental and physical health, quality of life and interpersonal relationships. Current management options are limited, as a reduction of dopaminergic medication often leads to worsening of motor symptoms or dopamine agonist withdrawal syndrome. The aim of this review was to investigate if ICDs improve, worsen, or remain stable after Subthalamic Nucleus Deep Brain Stimulation (STN-DBS). We reviewed retrospective, prospective and randomized-controlled studies published between 2000 and 2019 examining the effect of STN-DBS on one or more ICDs. The number of participants, time of follow-up, methods used to measure ICDs, type of ICDs, the incidence of ICDs before STN-DBS, the incidence of improvement (remission or reduction) of ICDs after STN-DBS, the incidence of de novo ICDs after STN-DBS, stimulation parameters, lead position, change in motor score and change in medication are reported for each study. Available studies suggest that ICDs improve after STN-DBS in most patients and that persisting new-onset ICDs induced by STN-DBS are rare. However, more randomized-controlled studies are needed to confirm the findings and to further investigate the underlying mechanisms.
Keywords: Parkinson's disease, impulse control disorders, deep brain stimulation, subthalamic nucleus stimulation, management, hyperdopaminergic behaviour.
CNS & Neurological Disorders - Drug Targets
Title:Management of Impulse Control Disorders with Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Volume: 19 Issue: 8
Author(s): Deborah Amstutz, Steffen Paschen, Martin Lenard Lachenmayer, Marie Elise Maradan-Gachet, Günther Deuschl, Paul Krack and Ines Debove*
Affiliation:
- Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern,Switzerland
Keywords: Parkinson's disease, impulse control disorders, deep brain stimulation, subthalamic nucleus stimulation, management, hyperdopaminergic behaviour.
Abstract: Impulse Control Disorders (ICDs) and related disorders are common side effects of dopaminergic treatment in Parkinson’s Disease (PD) and are associated with negative effects on mental and physical health, quality of life and interpersonal relationships. Current management options are limited, as a reduction of dopaminergic medication often leads to worsening of motor symptoms or dopamine agonist withdrawal syndrome. The aim of this review was to investigate if ICDs improve, worsen, or remain stable after Subthalamic Nucleus Deep Brain Stimulation (STN-DBS). We reviewed retrospective, prospective and randomized-controlled studies published between 2000 and 2019 examining the effect of STN-DBS on one or more ICDs. The number of participants, time of follow-up, methods used to measure ICDs, type of ICDs, the incidence of ICDs before STN-DBS, the incidence of improvement (remission or reduction) of ICDs after STN-DBS, the incidence of de novo ICDs after STN-DBS, stimulation parameters, lead position, change in motor score and change in medication are reported for each study. Available studies suggest that ICDs improve after STN-DBS in most patients and that persisting new-onset ICDs induced by STN-DBS are rare. However, more randomized-controlled studies are needed to confirm the findings and to further investigate the underlying mechanisms.
Export Options
About this article
Cite this article as:
Amstutz Deborah , Paschen Steffen , Lachenmayer Lenard Martin , Maradan-Gachet Elise Marie , Deuschl Günther , Krack Paul and Debove Ines *, Management of Impulse Control Disorders with Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2020; 19 (8) . https://dx.doi.org/10.2174/1871527319666200720105553
DOI https://dx.doi.org/10.2174/1871527319666200720105553 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Big Data Mining for CNS Diseases Analysis and Treatment: Focusing on Drug Target Discovery
Central nervous system (CNS) diseases, including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, represent a major global health challenge. Despite significant research efforts, the complexity and multifactorial nature of these diseases hinder the development of effective treatments. The rise of big data analytics and high-throughput technologies ...read more
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently, there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system and neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural and Functional Determinants of γ-Secretase, an Intramembrane Protease Implicated in Alzheimers Disease
Current Genomics An Overview of Green Chromatographic Analysis from Pharmaceutical Preparations
Current Analytical Chemistry Astrocytes: Targets for Neuroprotection in Stroke
Central Nervous System Agents in Medicinal Chemistry Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research Dopamine D5 Receptors: A Challenge to Medicinal Chemists
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Strategies to Improve the Functions and Redox State of the Immune System in Aged Subjects
Current Pharmaceutical Design Natural Marine Anti-inflammatory Products
Mini-Reviews in Medicinal Chemistry Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Adiponectin as a Regulator of Vascular Redox State: Therapeutic Implications
Recent Patents on Cardiovascular Drug Discovery Prediction of Biological Activity Spectra for Substances: Evaluation on the Diverse Sets of Drug-Like Structures
Current Medicinal Chemistry Antibody Recognition of Fluorinated Haptens and Antigens
Current Topics in Medicinal Chemistry Translating Nucleic Acid Amplification Assays to the Microscale: Lab on a Chip for Point-of-Care Molecular Diagnostics
Current Analytical Chemistry Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Current Alzheimer Research The Bioinorganic Chemistry of Methimazole Based Soft Scorpionates
Current Bioactive Compounds Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design In Silico Drug Repositioning for Chagas Disease
Current Medicinal Chemistry Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Current Enzyme Inhibition